HomePress-release

Redding, California - June 7, 2024

North America Tissue Diagnostics Market to be Worth $2.96 Billion by 2030

North America Tissue Diagnostics Market by Product Type (Antibodies, Kits, Reagents, Instruments [Slide Stainer, Scanner]), Technology (Digital Pathology, IHC, ISH, H&E Staining), Cancer Type (Breast, NSCLC, Colorectal, Prostate), and End User - Forecast to 2030

Meticulous Research^®—a leading market research company, published a research report titled, ‘North America Tissue Diagnostics Market by Product Type (Antibodies, Kits, Reagents, Instruments [Slide Stainer, Scanner]), Technology (Digital Pathology, IHC, ISH, H&E Staining), Cancer Type (Breast, NSCLC, Colorectal, Prostate), and End User - Forecast to 2030.’

According to this latest publication from Meticulous Research^®, the North America tissue diagnostics market is expected to register a CAGR of 7% from 2024 to reach $2.96 billion by 2030. The growth of North America tissue diagnostics market is mainly attributed to the increasing prevalence of cancer cases, rising healthcare expenditures, advanced infrastructure for cancer diagnosis, recommendations/guidelines and programs for cancer screening and government initiatives for cancer research. Further, the inclination toward personalized healthcare, growing awareness regarding early disease diagnosis, and adoption of digital pathology & automation in tissue diagnostics offer significant growth opportunities for players in this market. However, stringent technical requirements and product issues & recalls are expected to hinder the growth of this market. A shortage of histopathologists challenges the North America tissue diagnostics market.

Key Players

The key players operating in the North America tissue diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (U.S.), Abcam plc (U.K.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.), BIO SB Inc.(U.S.), Bio-Genex Laboratories (U.S.), HOLOGIC, INC. (U.S.), and Sakura Finetek Japan Co., Ltd. (Japan).

North America Tissue Diagnostics Market: Future Outlook

The North America tissue diagnostics market is segmented by product type [Consumables {kits & reagents, and antibodies}, Instruments}, technique {immunohistochemistry (IHC), in-situ hybridization (ISH), digital pathology, H&E and special staining, molecular diagnostics, and other techniques}, application {breast cancer, lung cancer, colorectal & gastrointestinal cancer, prostate cancer, lymphoma, and other applications}, end user { hospitals & diagnostic laboratories, research institutes, pharmaceutical companies, and contract research organizations}], and country. The study also evaluates industry competitors and analyzes their market share at the country level.

Among all the product types studied in the report, the consumables segment is expected to grow fastest during the forecast period. The consumables are further segmented into kits & reagents, and antibodies. The kits & reagent segment is expected to account for the largest share of the North America tissue diagnostics market in 2024. Factors such as the frequent use of assays & kits in detecting several infectious diseases and several product launches contribute to the large share of the kits & reagents segment. For instance, in May 2022, QIAGEN N.V. (Netherlands) launched the ‘therascreen EGFR Plus RGQ PCR Kit’. This kit enables the detection of all currently known activating and resistance EGFR mutations.

Among all the techniques studied in the report, the digital pathology segment is expected to grow fastest during the forecast period. Digital pathology, or whole slide imaging and telepathology, produces high-resolution digital images from tissue sections placed on glass slides. Large biopharmaceuticals and clinical research organizations (CROs) prefer digital pathology for streamlining drug development processes in discovery, pre-clinical and clinical trials.

Among all the applications studied in the report, in 2024, the breast cancer segment is expected to account for the largest share of the North America tissue diagnostics market. The large market share of this segment is attributed to the growing number of breast cancer cases, screening programs such as the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), Evidence-Based Cancer Control Programs (EBCCP), North Carolina Breast Cancer Screening Program and the increasing government initiatives & private organizations to improve awareness about breast cancer.

Among all the end users studied in the report, the hospitals & diagnostics laboratories segment is expected to account for the largest share of the North America tissue diagnostics market in 2024. The large market share of this segment is primarily attributed to the rising laboratory automation, availability of well-equipped systems, growing prevalence of cancer, increasing government initiatives, and rise in healthcare spending.

Among all the countries studied in the report, the U.S. is expected to account for the largest share of the North America tissue diagnostics market in 2024. The large market share of the U.S. is attributed to the growing prevalence of cancer and government support for cancer research. For instance, according to the GLOBOCAN, in 2020, there were 2.28 million new cancer cases and 612,390 cancer deaths in the U.S. The new cancer cases are expected to increase to 3.12 million by 2040. Hence, increasing cancer incidence and mortality is expected to stimulate the region's demand for advanced diagnostic procedures.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5554

Key questions answered in the report-

What are the high-growth market segments regarding the product type, techniques, application, end user, and country?
What was the historical market for North America tissue diagnosis?
What are the market forecasts and estimates for 2024–2030?
What are the major drivers, restraints, challenges, and opportunities in the North America tissue diagnostics market?
Who are the major players in the North America tissue diagnostics market?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & Wastewater Technologies

Miscellaneous / Others

Redding, California - June 7, 2024

North America Tissue Diagnostics Market to be Worth $2.96 Billion by 2030

North America Tissue Diagnostics Market by Product Type (Antibodies, Kits, Reagents, Instruments [Slide Stainer, Scanner]), Technology (Digital Pathology, IHC, ISH, H&E Staining), Cancer Type (Breast, NSCLC, Colorectal, Prostate), and End User - Forecast to 2030

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies